Пинатузумаб ведотин

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

DB15432

1313706-14-7

immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, Blymphocyte cell adhesion molecule, BL-CAM, Leu-14)], humanized monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-450) [humanized VH (Homo sapiens IGHV3- 66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide (if not conjugated) with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') - Homo sapiens IGKC*01 (113'-219')]; dimer (229-229":232-232")- bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valylcitrullinyl-p-aminobenzylcarbamate (mc-val-cit-PABC) linke

C₆₇₄₈H₁₀₃₇₇N₁₇₇₃O₂₀₈₃S₄₄

151081,21 г/моль

Поделиться этой страницей